RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.

Fiche publication


Date publication

février 2019

Journal

EBioMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr COLLIN Françoise, Pr MERLIN Jean-Louis, Dr MIRJOLET Céline, Pr NOEL Georges, Pr TRUC Gilles


Tous les auteurs :
Mirjolet C, Merlin JL, Truc G, Noël G, Thariat J, Domont J, Sargos P, Renard-Oldrini S, Ray-Coquard I, Liem X, Chevreau C, Lagrange JL, Mahé MA, Collin F, Bonnetain F, Bertaut A, Maingon P

Résumé

Radiation-induced sarcoma (RIS) is a rare but serious event. Its occurrence has been discussed during the implementation of new radiation techniques and justified appropriate radioprotection requirements. New approaches targeting intrinsic radio-sensitivity have been described, such as radiation-induced CD8 T-lymphocyte apoptosis (RILA) able to predict late radio-induced toxicities. We studied the role of RILA as a predisposing factor for RIS as a late adverse event following radiation therapy (RT).

Référence

EBioMedicine. 2019 Feb 28;: